Evidence map›Paper›PMID 41306516›Full record

ArticlebioRxiv : the preprint server for biology2025

Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate anti-proliferative effects.

Samuel A Blackman, Ahlam N Qerqez, Alison G Lee, Nicole V Johnson, Justin M Owens, Grace S Lai, Emma C Aldrich, Kayla G Sprenger, Jangsoon Lee, Sophie Verrier and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Samuel A BlackmanMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.
Ahlam N QerqezMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.ORCID 0000-0003-4694-5619
Alison G LeeInterdisciplinary Life Sciences Graduate Program, The University of Texas at Austin, North Hackerman Building, 100 East 24th St, NHB 4500, Austin, TX 78712.
Nicole V JohnsonInterdisciplinary Life Sciences Graduate Program, The University of Texas at Austin, North Hackerman Building, 100 East 24th St, NHB 4500, Austin, TX 78712.ORCID 0000-0003-4351-125X
Justin M OwensMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.ORCID 0009-0001-5744-787X
Grace S LaiMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.
Emma C AldrichDepartment of Chemical and Biological Engineering, University of Colorado Boulder, 3415 Colorado Ave, Boulder, CO 80309, USA.ORCID 0000-0002-5729-4738
Kayla G SprengerDepartment of Chemical and Biological Engineering, University of Colorado Boulder, 3415 Colorado Ave, Boulder, CO 80309, USA.ORCID 0000-0002-7505-7920
Jangsoon LeeUniversity of Hawaii Comprehensive Cancer Center, University of Hawaii, 701 Ilao St, Honolulu, HI 96813, USA.ORCID 0000-0002-6862-5686
Sophie VerrierAO Research Institute Davos, Clavadelerstrasse 8, 7270 Davos Platz, Switzerland.ORCID 0000-0003-2478-2804
Martin J StoddartAO Research Institute Davos, Clavadelerstrasse 8, 7270 Davos Platz, Switzerland.ORCID 0000-0002-9538-1517
Annalee W NguyenMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.ORCID 0000-0003-1268-7164
Jennifer A MaynardMcKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712.ORCID 0000-0002-0363-8486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies blocking the function of vascular endothelial growth factor A (VEGFA) remain a promising therapeutic strategy, especially when combined with check-point inhibitors, but their efficacy is limited by tumor resistance. This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model. By contrast, antibodies binding PlGF-2 or VEGFA to block NRP1 significantly reduced proliferation of Caki-I kidney carcinoma cells

Indexed as

angiogenesisantibodiesheparinNRP1phage displayPlGFVEGFAVEGFR1

Identifiers

PMID41306516
PMCPMC12645800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.